Lormetazepam is a benzodiazepine for short-term severe insomnia. UK indication. Warnings/funding review; no prescription.
- Confirm your pack/country with the pharmacist.
- Dependence can develop during prescribed use; agree an ending plan. MHRA.
- Suspected excess intake needs immediate emergency help. MHRA.
- Pregnancy and breastfeeding need individual medical assessment. UK leaflet.
- Commercially supported efficacy is excluded from the independent verdict.
Table of contents
- Evidence summary
- Lormetazepam and foreign product names
- How lormetazepam works
- Insomnia treatment assessment
- Lifestyle and supplement evidence
- What the independent evidence screen establishes
- Emergency and adverse effects
- Medicine/alcohol interactions
- Contraindications, pregnancy/breastfeeding
- Use, driving and withdrawal
- Animal evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| UK indication | Label | Maker-produced | Context; efficacy uncleared. |
| Historical study | Original preview | Commercial grant | Design/disclosure only; efficacy excluded. |
| Dependence | Class warning | Agency/company-input gaps | Safety communication, not comparative benefit. |
| Breastfeeding | Leaflet; SPS | Maker/class guidance | Different scope; specialist assessment. |
| Use frequency | Original table | Agency route | England community items; no patient/global ranking. |
Lormetazepam and foreign product names
UK leaflet: 0.5/1 mg tablets. Pack identity.
Spain’s Noctamid text lists 1/2 mg tablets and 2.5 mg/ml drops, with perioperative scope beyond insomnia. It does not authorize UK use or conversion. Spanish distinction.
France’s group identifies Noctamide as a lormétazépam reference product; a register entry does not prove stock. French identity.
Ireland’s Loramet entry is withdrawn from 17 September 2008 and not marketed. This says nothing about all countries. Irish record.
Confirm instructions from your dispensed pack.
How lormetazepam works
The Spanish label describes benzodiazepine-receptor action enhancing GABA-related inhibition. A mechanism explains sedation, not independent superiority or personal safety. Mechanism.
Mechanistic plausibility and patient outcomes need different evidence. A medicine can act on its proposed biological target while questions about durability, daytime function, dependence and the best option for a particular person remain unsettled. The financial screen therefore assesses clinical outcome claims separately from the explanation of how the drug acts.
Insomnia treatment assessment
NHS care looks for the cause of insomnia and may offer cognitive behavioural therapy or sleep-clinic referral. Sleep apnoea, pain, mood disorders, medicines and sleep timing may need their own assessment. Care context.
UK: usually days–two weeks; maximum four weeks including tapering. Reassess extensions. Duration.
At the appointment, ask what problem the prescription is intended to address, what change would count as worthwhile, and which professional will review it. Ask how persistent symptoms or conflicting instructions should be handled. These prompts support a consultation; they do not establish that medication is the appropriate next step.
Lifestyle and supplement evidence
Regular waking time, a dark/quiet bedroom, daytime activity and avoiding late caffeine/alcohol are NHS sleep-habit measures. Persistent disruptive symptoms merit assessment. Sleep habits.
Supplements can interact with medicines; their marketing and sale do not establish drug-style safety or effectiveness. Share exact ingredients with the pharmacist. Supplement limits.
This screen establishes no supplement as a proven replacement for lormetazepam or a withdrawal treatment. A claim about improving sleep in a different setting would need its own trial, product identity and financial review before it could answer that question. Adding another product should not serve as a way to bypass the prescribing review.
What the independent evidence screen establishes
The May 2007 study’s visible abstract describes 30 elderly outpatients, open-label randomisation and brief follow-up. The manuscript received a Schering-SpA educational grant. Its reported benefit is excluded from this independent verdict. Design and finance.
The January 2026 review assessed communication of dependence-related risks using company data among other inputs. Efficacy, dose and indication were outside that review. Review boundary.
England’s FY2025/26 table records 8,369 community prescription items. Use count.
Items are not patients, hospital supply, insomnia-only use or a worldwide popularity comparison. Count boundary.
No financially cleared long-term superiority estimate is established by the originals adopted here. That finding is an evidence limit, rather than a claim that no patient benefits. Product instructions, an old study’s reported results, a safety review and dispensing frequency cannot be substituted for one another.
Emergency and adverse effects
Suspected benzodiazepine overdose: call 999 immediately in the UK, local emergency services elsewhere. Do not wait for symptoms. Emergency resource.
Excess tablets: immediate doctor/casualty attention; bring container. Leaflet.
Do not drive yourself, induce vomiting or give food/drink after suspected poisoning. Follow emergency-service instructions. Safe care boundary.
Sudden lip/mouth/throat/tongue swelling, swallowing or breathing difficulty, or collapse needs immediate emergency help: 999 in the UK. Serious allergy.
Sleepiness, dizziness or poor coordination can occur; confusion, hallucinations, aggression, memory loss, breathing difficulty or jaundice require immediate advice. Adverse-effect warning.
If life is at risk or you cannot keep yourself or someone else safe, get emergency help immediately. Mental-health emergency.
After a fall, inability to get up or possible head/back/neck/hip injury requires immediate emergency help. Injury action.
Urgent warnings override continuity; packaging mustn’t delay care.
Medicine/alcohol interactions
Benzodiazepines with opioids can cause sedation, respiratory depression, coma and death. Co-prescribing is reserved for situations without an alternative, with close monitoring. Breathing difficulty or severe sedation needs immediate medical attention. Opioid warning.
Avoid alcohol; review sedatives, muscle relaxants, antihypertensives, theophylline/aminophylline and enzyme inhibitors. Product interactions.
Pharmacist: reconcile actual medicines and instructions; omissions aren’t clearance.
Contraindications, pregnancy/breastfeeding
Contraindications: severe respiratory insufficiency, sleep apnoea, benzodiazepine/component allergy, myasthenia gravis, severe hepatic failure. Assess organ disease/frailty/glaucoma. Restrictions.
Not primary psychosis/depression treatment or sole depression-associated-insomnia therapy; children’s treatment unevaluated. Scope.
Pregnancy: consult prescriber before use; late exposure can cause neonatal floppiness, hypothermia, breathing/feeding problems and withdrawal. UK: no breastfeeding use. Reproductive warnings.
SPS benzodiazepine guidance covers healthy full-term infants with poor/limited evidence, and does not individually assess lormetazepam. Seek specialist advice; no bedsharing after sedating medicine. Class-guidance limits.
Do not treat general guidance for another drug or a healthy full-term infant as an individual answer for this medicine, a premature infant or an unwell infant. Ask the prescriber and specialist feeding service to reconcile the exact product instructions with your circumstances. No stopping, switching or feeding schedule is provided here.
Use, driving and withdrawal
Missed dose: next when due; never double. Leaflet.
Do not drive until effects are known, or while impaired, even when prescribed. Driving.
Agree reviews and a gradual, adaptable withdrawal plan. Assess new symptoms for withdrawal versus recurrent/new illness; abrupt cessation needs exceptional medical justification. Withdrawal care.
Physical dependence is not necessarily addiction. Sudden reduction can cause withdrawal, including seizures; a medical emergency needs emergency help. Withdrawal can take weeks or months. Stopping boundary.
Contact the prescriber about supply disruption. Ask whom to contact if the agreed plan becomes difficult to follow, and arrange follow-up rather than inventing a dose conversion or taper. Be candid about actual use so the written plan can be based on the facts. This guide provides no dose, missed-dose catch-up scheme or withdrawal calendar.
Animal evidence
Rat fertility does not establish human reproductive safety. Preclinical.
No animal or test-tube outcome is used here to prove human insomnia benefit, safe pregnancy, breastfeeding safety or a personal regimen. A laboratory mechanism, a short human observation and a clinical safety warning have different roles. This guide offers no animal-to-human conversion and makes no assumption that an unreported finding is absent from all research.
Funding and source roles
Research funding at a glance
45 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS: editorial policy | DHSC funds national website; corporate sponsorship/advertising excluded by policy. Individual provider finances unverified. | UK | Tier 3 — institutional self-report | C provisional. October 2022; October 2025 review due passed. Page/trial interests unclosed. |
| MHRA: FY2025/26 accounts | Industry statutory/nonstatutory fees, DHSC grants, research/services. Warning/adviser allocation unknown. | London, UK | Tier 3 — institutional self-report | B provisional. Selected finance passages; not full adviser or product-payment clearance. |
| SPS: commissioning | Page names NHS England commissioning and trust hosts; current guidance/reviewer allocation unknown. | England, UK | Tier 3 — institutional self-report | C provisional. Page contracts end March 2026; subsequent arrangements not established. |
| NICE: FY2025/26 accounts | DHSC/public funding, appraisal/advice fees, research and commercial income; NG215 allocation unknown. | London/Manchester, UK | Tier 3 — institutional self-report | B provisional. Selected original income/related-party notes; committee payment chain unclosed. |
| NICE: NG215 committee | Guideline personnel self-listed; current personal contracts/disclosures unclosed. | UK | Tier 3 — institutional self-report | C provisional. File metadata October 2021; current interests unclosed. |
| NCCIH: appropriations history | Federal institute’s appropriations table; safety-page allocation unknown. | Bethesda, US | Tier 3 — institutional self-report | B provisional. Displayed series ends FY2024; not current FY2026 allocation. |
| NCCIH: gift authority | Separate conditional/unconditional gift route; actual donors/receipts unclosed. | Bethesda, US | Tier 3 — institutional self-report | B provisional. Authority permits gifts; no specific private page funder identified. |
| Datapharm: eMC model | Pharmaceutical subscribers pay hosting; product fee/shareholder chain unclosed. | Leatherhead, UK | Tier 4 — commercial publisher self-report | D. Original publication process; regulator approval does not clear efficacy independence. |
| NHSBSA: FY2025/26 accounts | Parliamentary funding, DHSC service contracts/public administration, other operating income. PCA allocation unknown. | Newcastle upon Tyne, UK | Tier 3 — institutional self-report | B provisional. Selected statements/notes; counts imply no clinical benefit. |
| Companies House: FY2025/26 accounts | Statutory fees, departmental/Treasury funding and Economic Crime Levy; not company capital. | Cardiff, UK | Tier 3 — institutional self-report | B provisional. Selected finance/office original; filings remain company supplied. |
| Genus: company register | Company-supplied identity; see registry finance. | Huddersfield, UK | Tier 3 — institutional self-report | C provisional. Active wholesaler; register warns accuracy not checked. |
| Genus: control register | STADA UK Holdings: at least 75% shares/votes and director-control rights. | England, UK | Tier 3 — institutional self-report | C provisional. Filed declaration; ultimate interests not fully cleared. |
| Genus: FY2025 filed accounts | Pharmaceutical sales/distribution, subsidiary dividends, group balances/secured guarantees. STADA/CapVest control; Bain (US)/Cinven (UK) reinvested. | Huddersfield, UK | Tier 4 — maker-produced; self-interest | D. Selected scanned pages; final group structure/product receipts unclosed. |
| STADA: March 2026 closing | CapVest majority acquisition completed; commercial medicine business. | Bad Vilbel, Germany | Tier 4 — maker-produced; self-interest | D. 31 March 2026 announcement; full investor/product ledger unclosed. |
| CapVest: investment model | Private-equity control investments; funds’ ultimate investors/receipts unclosed. | London/New York/Dublin | Tier 4 — investor-produced; self-interest | D. Own strategy/locations; no fund or cap-table audit. |
| Aenova: 2024 group policy | Contract-manufacturing group includes Haupt Pharma Münster. | Germany | Tier 4 — maker-produced; self-interest | D. Dated corporate list; exact batch contracts unclosed. |
| Aenova: FY2024 report | Manufacturing/service revenues, debt and equity/refinancing. | Starnberg, Germany | Tier 4 — maker-produced; self-interest | D. Selected published statements; not current product receipts or whole audit. |
| Aenova: August 2024 closing | Kühne Holding majority, BC Partners minority after completed acquisition. | Starnberg, Germany; Swiss buyer (row below) | Tier 4 — maker-produced; self-interest | D. 29 August 2024 closing; later ultimate stakes unclosed. |
| Kühne Holding: own profile | Klaus-Michael Kühne’s family holding; strategic investments, property and asset management. Accounts/ultimate interests unclosed. | Schindellegi, Switzerland | Tier 4 — investor-produced; self-interest | D. Own business/contact description; no investment-level receipts or cap-table clearance. |
| Teofarma: own company profile | Private company owns/markets medicine brands and authorisations; owners/debt/accounts unclosed. | Pavia, Italy | Tier 4 — maker-produced; self-interest | D. Own business description; no full beneficial-owner or revenue audit. |
| French database: publisher | ANSM publisher; separate ANSM budget below. Hosting-company ownership unclosed. | Saint-Denis, France | Tier 3 — institutional self-report | C provisional. Own legal notice; registry-page allocation unknown. |
| ANSM: initial 2025 budget | Health-insurance allocation plus own revenues; initial plan, not final/current accounts. | Saint-Denis, France | Tier 3 — institutional self-report | C provisional. November 2024 approval; own-revenue/page chains incomplete. |
| HPRA: FY2025 accounts | Medicine/compliance/device fees, Department of Health funding and other income. | Dublin, Ireland | Tier 3 — institutional self-report | B provisional. Selected income notes; pension-qualified audit; product-record allocation unknown. |
| Schering: FY2005 statements | Pharmaceutical sales; Schering S.p.A., Milan, listed 100% subsidiary. | Berlin, Germany; Milan, Italy | Tier 4 — maker-produced; self-interest | D. Historical maker filing, despite SEC hosting; grant receipts unclosed. |
| Bayer: FY2006 report | Bayer acquired Schering; pharmaceutical sales, debt/equity acquisition finance. | Germany | Tier 4 — maker-produced; self-interest | D. Historical selected passages; no paper-payment or current ownership inference. |
| UK professional label | Genus/STADA; corporate/eMC rows above; allocation unknown. | UK | Tier 4 — maker-produced; self-interest | D. Revised 19 March 2026; posted 8 April. Efficacy excluded. |
| UK patient leaflet | STADA/Haupt Pharma Münster; corporate rows. | UK; Münster, Germany | Tier 4 — maker-produced; self-interest | D. February 2026; efficacy excluded. |
| MHRA: January 2026 warning | Agency finance above; review includes company data; adviser chain unclosed. | UK | Tier 3 — fee-linked regulatory context | C provisional. Class risk communication; no drug efficacy comparison. |
| MHRA: benzodiazepine resource | Agency finance above; specific resource/adviser allocation unknown. | UK | Tier 3 — fee-linked regulatory context | C provisional. Two-page class resource; specialist epilepsy scope excluded. |
| MHRA: opioid combinations | Agency finance above; warning/contributor allocation unknown. | UK | Tier 3 — fee-linked regulatory context | C provisional. March 2020 class warning, not an individual risk estimate. |
| NHS: insomnia | NHS policy above; page/reviewer/trial allocation unknown. | UK | Tier 2 — public context; provisional | B provisional. March 2024; clinical context only. |
| NHS: anaphylaxis | NHS policy above; page/reviewer/trial allocation unknown. | UK | Tier 2 — public context; provisional | C provisional. June 2023; June 2026 due passed; clinical context only. |
| NHS: poisoning | NHS policy above; page/reviewer/trial allocation unknown. | UK | Tier 2 — public context; provisional | B provisional. June 2025; clinical context only. |
| NHS: falls | NHS policy above; page/reviewer/trial allocation unknown. | UK | Tier 2 — public context; provisional | B provisional. March 2025; clinical context only. |
| NHS: mental-health emergency | NHS policy above; page/reviewer/trial allocation unknown. | UK | Tier 2 — public context; provisional | C provisional. April 2023; April 2026 due passed; clinical context only. |
| SPS: benzodiazepine breastfeeding | Service finance above; guidance/evidence/author chain unclosed. | England, UK | Tier 2 — public context; provisional | C provisional. February 2024; healthy full-term scope, poor/limited evidence. |
| NICE: NG215 withdrawal | Institutional/personnel rows above; trial and member finances unclosed. | UK | Tier 2 — public context; provisional | C provisional. April 2022; context, no independent drug ranking. |
| NCCIH: supplement safety | Institutional public/gift routes above; safety-page/underlying studies unclosed. | US | Tier 2 — public context; provisional | C provisional. January 2019 footer; supplement efficacy not established here. |
| De Vanna et al.: 2007 study | Schering-SpA manuscript grant; subscription publisher; authors report no directly relevant conflict. Receipt/publisher-owner chains unclosed. | Trieste, Italy | Tier 4 — commercially supported; self-interest | D. Original preview/acknowledgments; full methods paywalled; efficacy excluded. |
| Spain: Noctamid label | Teofarma maker document; company route above; regulator approval not independence. | Spain; Italian holder | Tier 4 — maker-produced; self-interest | D. February 2022 text; foreign instructions not UK conversion. |
| France: Noctamide group | Database publisher/budget above; exact record allocation unknown. | France | Tier 2 — public context; provisional | C provisional. Ingredient/reference identity; not stock or clinical guidance. |
| Ireland: Loramet record | Fee-linked regulator above; dated holder Meda Health Sales Ireland. | Ireland | Tier 3 — fee-linked regulatory context | C provisional. Withdrawn September 2008/not marketed; no global inference. |
| NHSBSA: lormetazepam items | Authority finance above; allocation/capture-chain interests unclosed. | England data; UK | Tier 2 — public context; provisional | B provisional. FY2025/26 community items; no benefit/popularity extrapolation. |
| NHSBSA: PCA release | Authority finance above; publication allocation unknown. | England/UK | Tier 2 — public context; provisional | B provisional. 4 June 2026 release; community reimbursement scope. |
| NHSBSA: PCA methodology | Authority finance above; contributor interests unclosed. | England/UK | Tier 2 — public context; provisional | B provisional. June 2026 methods; items differ from patients/efficacy. |
Frequently asked questions
Can I substitute Noctamid drops for UK tablets? No self-conversion is provided; confirm the exact country/product instructions with a pharmacist. Source.
Can dependence occur during prescribed use? Yes, including short-term use. Discuss changes with the prescriber rather than increasing or stopping yourself. Source.
What should I do after suspected overdose? Get emergency help immediately. MHRA directs 999 in the UK; use local emergency services elsewhere. Source.
Does SPS clear lormetazepam while breastfeeding? No individual lormetazepam assessment appears there. The exact maternal/infant circumstances need specialist review. Source.
Does the course limit mean abrupt withdrawal? No. Discuss an adaptable individual ending plan, including unexpected symptoms or supply difficulties. Source.
Does this guide provide a personal dose? No. The clinician and dispensing pharmacist must confirm the exact product and individual written plan.
Sources and funding notes
Reviewed 5 October 2026. Each row distinguishes actual document scope, dated financial links and remaining access gaps. Institutional education and maker warnings are context; sponsored efficacy is excluded. Source hosting does not establish source independence.
- NHS: editorial policy — National website process only.
- MHRA: FY2025/26 accounts — Agency finance only.
- SPS: commissioning — Service finance, not each host’s accounts.
- NICE: FY2025/26 accounts — Institutional funding only.
- NICE: NG215 committee — Personnel identity only.
- NCCIH: appropriations history — Dated institutional public funding.
- NCCIH: gift authority — Permitted finance route only.
- Datapharm: eMC model — Hosting revenue only.
- NHSBSA: FY2025/26 accounts — Authority finance only.
- Companies House: FY2025/26 accounts — Registry host finance only.
- Genus: company register — Registered legal identity.
- Genus: control register — Declared immediate control.
- Genus: FY2025 filed accounts — Maker’s financial/ownership context.
- STADA: March 2026 closing — Completed ownership event, not benefit.
- CapVest: investment model — Investor incentives only.
- Aenova: 2024 group policy — Manufacturer group identity only.
- Aenova: FY2024 report — Commercial finance only.
- Aenova: August 2024 closing — Dated completed ownership event.
- Kühne Holding: own profile — Buyer’s model and jurisdiction only.
- Teofarma: own company profile — Spanish holder’s commercial route.
- French database: publisher — Publisher identity only.
- ANSM: initial 2025 budget — Dated budget routes only.
- HPRA: FY2025 accounts — Irish regulator finance only.
- Schering: FY2005 statements — Historical grant-payer chain.
- Bayer: FY2006 report — Dated parent financing context.
- UK professional label — UK prescribing context.
- UK patient leaflet — Tablet instructions.
- MHRA: January 2026 warning — Dependence and withdrawal warning.
- MHRA: benzodiazepine resource — Overdose/dependence safety context.
- MHRA: opioid combinations — Interaction safety context.
- NHS: insomnia — Assessment/CBT context.
- NHS: anaphylaxis — Emergency allergy instructions.
- NHS: poisoning — Emergency care boundary.
- NHS: falls — Emergency injury assessment.
- NHS: mental-health emergency — Immediate danger care.
- SPS: benzodiazepine breastfeeding — Class guidance, no lormetazepam clearance.
- NICE: NG215 withdrawal — Individual withdrawal-care framework.
- NCCIH: supplement safety — Interaction/quality context only.
- De Vanna et al.: 2007 study — Historical design and disclosure only.
- Spain: Noctamid label — Formulation/mechanism context.
- France: Noctamide group — Alias identity only.
- Ireland: Loramet record — Historical alias/market-record context.
- NHSBSA: lormetazepam items — Bounded medicine-use frequency.
- NHSBSA: PCA release — Dataset/date identity.
- NHSBSA: PCA methodology — Dataset coverage boundary.
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.